Inovio Stock Plummets 37% on Public Offering News

Offering Triggers Major Stock Decline

Inovio Pharmaceuticals (NASDAQ:INO) shares experienced a significant 37.1% decline on Thursday following the announcement of a dilutive public offering aimed at raising capital.

Details of the Public Offering

The biotechnology firm priced an underwritten offering of 12.5 million shares of common stock at $1.40 per share. The offering also includes accompanying Series A and Series B warrants, each allowing the purchase of up to 12.5 million additional shares at the same exercise price. The company expects to generate gross proceeds of approximately $17.5 million from the sale of shares, before expenses.

Market Reaction and Impact

The market reacted negatively due to the dilutive nature of the offering, which increases the total number of shares outstanding and can reduce the value of existing shares. The funds are intended to support Inovio's development of DNA medicines for various diseases. Piper Sandler is serving as the sole manager for the transaction.

Summary

Inovio's move to raise capital through this offering has led to a substantial short-term drop in its stock value. The company's future performance will depend on how effectively it utilizes these funds to advance its clinical programs.

FAQ

Q: Why did Inovio's stock price fall?

A: The stock price fell 37.1% after Inovio announced a public offering of shares and warrants, which is dilutive to existing shareholders.

Q: How much money is Inovio raising?

A: Inovio expects to receive gross proceeds of approximately $17.5 million from the share offering, before deducting fees and expenses.

Source: Investing.com